AstraZeneca, Eli Lilly and Roche among pharmaceutical companies upgraded for high returns on R&D investments, analysts sayMarket Watch • 09/14/22
ENHERTU® Continues to Demonstrate Clinically Meaningful Tumor Response in Patients with HER2 Mutant Metastatic Non-Small Cell Lung CancerBusiness Wire • 09/11/22
Gatehouse Bio Extends Its Partnership with AstraZeneca to Develop RNA Therapeutics for Heart FailureBusiness Wire • 09/08/22
AstraZeneca wins injunction preventing former executive from joining GSKProactive Investors • 09/01/22
AstraZeneca aims to transform cancer outcomes with new data across industry-leading portfolio at ESMO 2022Business Wire • 08/24/22
LogicBio Therapeutics Reports Second Quarter 2022 Financial Results and Provides Corporate UpdatePRNewsWire • 08/15/22
Enhertu significantly delayed breast cancer progression in trial, AstraZeneca saysMarket Watch • 08/15/22
ENHERTU® Significantly Delayed Disease Progression in DESTINY-Breast02 Phase 3 Trial Versus Physician's Choice of Treatment in Patients with HER2 Positive Metastatic Breast CancerBusiness Wire • 08/15/22
ENHERTU® Approved in the U.S. as the First HER2 Directed Therapy for Patients with Previously Treated HER2 Mutant Metastatic Non-Small Cell Lung CancerBusiness Wire • 08/12/22
Datopotamab Deruxtecan-Based Combinations Show Promising Clinical Activity in Patients with Advanced Non-Small Cell Lung CancerBusiness Wire • 08/09/22